BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37270536)

  • 1. Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy.
    de Kort AM; Kuiperij HB; Jäkel L; Kersten I; Rasing I; van Etten ES; van Rooden S; van Osch MJP; Wermer MJH; Terwindt GM; Schreuder FHBM; Klijn CJM; Verbeek MM
    Alzheimers Res Ther; 2023 Jun; 15(1):102. PubMed ID: 37270536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-Amyloid in CSF: Biomarker for preclinical cerebral amyloid angiopathy.
    van Etten ES; Verbeek MM; van der Grond J; Zielman R; van Rooden S; van Zwet EW; van Opstal AM; Haan J; Greenberg SM; van Buchem MA; Wermer MJ; Terwindt GM
    Neurology; 2017 Jan; 88(2):169-176. PubMed ID: 27903811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal Fluid Biomarkers and Amyloid-β Elimination from the Brain in Cerebral Amyloid Angiopathy-Related Inflammation.
    Sakai K; Noguchi-Shinohara M; Tanaka H; Ikeda T; Hamaguchi T; Kakita A; Yamada M; Ono K
    J Alzheimers Dis; 2023; 91(3):1173-1183. PubMed ID: 36565118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy.
    Rasing I; Voigt S; Koemans EA; de Kort AM; van Harten TW; van Etten ES; van Zwet EW; Stoops E; Francois C; Kuiperij BH; Klijn CJM; Schreuder FHBM; van der Weerd L; van Osch MJP; van Walderveen MAA; Verbeek MM; Terwindt GM; Wermer MJH
    Alzheimers Res Ther; 2024 Apr; 16(1):86. PubMed ID: 38654326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal Fluid Profile of Tau, Phosphorylated Tau, Aβ42, and Aβ40 in Probable Cerebral Amyloid Angiopathy.
    Grangeon L; Paquet C; Guey S; Zarea A; Martinaud O; Rotharmel M; Maltête D; Quillard-Muraine M; Nicolas G; Charbonnier C; Chabriat H; Wallon D
    J Alzheimers Dis; 2022; 87(2):791-802. PubMed ID: 35367960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aβ38 and Aβ43 do not differentiate between Alzheimer's disease and cerebral amyloid angiopathy.
    Dargvainiene J; Jensen-Kondering U; Bender B; Berg D; Brüggemann N; Flüh C; Markewitz R; Neumann A; Röben B; Röcken C; Royl G; Schulte C; Wandinger KP; Weiler C; Margraf NG; Kuhlenbäumer G
    Ann Clin Transl Neurol; 2024 Mar; 11(3):806-811. PubMed ID: 38186185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer's disease.
    Shahpasand-Kroner H; Klafki HW; Bauer C; Schuchhardt J; Hüttenrauch M; Stazi M; Bouter C; Wirths O; Vogelgsang J; Wiltfang J
    Alzheimers Res Ther; 2018 Dec; 10(1):121. PubMed ID: 30526652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy.
    Banerjee G; Ambler G; Keshavan A; Paterson RW; Foiani MS; Toombs J; Heslegrave A; Dickson JC; Fraioli F; Groves AM; Lunn MP; Fox NC; Zetterberg H; Schott JM; Werring DJ
    J Alzheimers Dis; 2020; 74(4):1189-1201. PubMed ID: 32176643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis.
    Charidimou A; Friedrich JO; Greenberg SM; Viswanathan A
    Neurology; 2018 Feb; 90(9):e754-e762. PubMed ID: 29386280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropsychiatric symptoms with focus on apathy and irritability in sporadic and hereditary cerebral amyloid angiopathy.
    Kaushik K; de Kort AM; van Dort R; van der Zwet RGJ; Siegerink B; Voigt S; van Zwet EW; van der Plas MC; Koemans EA; Rasing I; Kessels RPC; Middelkoop HAM; Schreuder FHBM; Klijn CJM; Verbeek MM; Terwindt GM; van Etten ES; Wermer MJH
    Alzheimers Res Ther; 2024 Apr; 16(1):74. PubMed ID: 38582898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Aβ reduction prevents progression of cerebral amyloid angiopathy.
    Schelle J; Wegenast-Braun BM; Fritschi SK; Kaeser SA; Jährling N; Eicke D; Skodras A; Beschorner N; Obermueller U; Häsler LM; Wolfer DP; Mueggler T; Shimshek DR; Neumann U; Dodt HU; Staufenbiel M; Jucker M
    Ann Neurol; 2019 Oct; 86(4):561-571. PubMed ID: 31359452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria.
    Renard D; Castelnovo G; Wacongne A; Le Floch A; Thouvenot E; Mas J; Gabelle A; Labauge P; Lehmann S
    J Neurol; 2012 Nov; 259(11):2429-33. PubMed ID: 22576334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased ratios of matrix metalloproteinases to tissue-type inhibitors in cerebrospinal fluid in sporadic and hereditary cerebral amyloid angiopathy.
    Vervuurt M; de Kort AM; Jäkel L; Kersten I; Abdo WF; Schreuder FHBM; Rasing I; Terwindt GM; Wermer MJH; Greenberg SM; Klijn CJM; Kuiperij HB; Verbeek MM
    Alzheimers Res Ther; 2023 Jan; 15(1):26. PubMed ID: 36717932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation.
    Renard D; Wacongne A; Ayrignac X; Charif M; Fourcade G; Azakri S; Le Floch A; Bouly S; Marelli C; Arquizan C; Hirtz C; Gabelle A; Thouvenot E; Lehmann S
    J Alzheimers Dis; 2016; 50(3):759-764. PubMed ID: 26757185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurotoxicity and physicochemical properties of Abeta mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease.
    Murakami K; Irie K; Morimoto A; Ohigashi H; Shindo M; Nagao M; Shimizu T; Shirasawa T
    J Biol Chem; 2003 Nov; 278(46):46179-87. PubMed ID: 12944403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presymptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy-Related Blood Metabolite Alterations.
    Chatterjee P; Fagan AM; Xiong C; McKay M; Bhatnagar A; Wu Y; Singh AK; Taddei K; Martins I; Gardener SL; Molloy MP; Multhaup G; Masters CL; Schofield PR; Benzinger TLS; Morris JC; Bateman RJ; Greenberg SM; Wermer MJH; van Buchem MA; Sohrabi HR; Martins RN;
    J Alzheimers Dis; 2021; 79(2):895-903. PubMed ID: 33361604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.
    van Steenoven I; van der Flier WM; Scheltens P; Teunissen CE; Lemstra AW
    Alzheimers Res Ther; 2019 Oct; 11(1):83. PubMed ID: 31601267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insights into Cerebral Amyloid Angiopathy Type 1 and Type 2 from Comparisons of the Fibrillar Assembly and Stability of the Aβ40-Iowa and Aβ40-Dutch Peptides.
    Rajpoot J; Crooks EJ; Irizarry BA; Amundson A; Van Nostrand WE; Smith SO
    Biochemistry; 2022 Jun; 61(12):1181-1198. PubMed ID: 35666749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of Rabbit Monoclonal Antibody to Amyloid-β38 (Aβ38): Increased Plasma Aβ38 Levels in Down Syndrome.
    Mehta PD; Patrick BA; Barshatzky M; Mehta SP; Frackowiak J; Mazur-Kolecka B; Miller DL
    J Alzheimers Dis; 2015; 46(4):1021-32. PubMed ID: 26402629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative methods for quantifying plasma biomarkers in Alzheimer's disease: Implications for the next frontier in cerebral amyloid angiopathy diagnostics.
    Muir RT; Ismail Z; Black SE; Smith EE
    Alzheimers Dement; 2024 Feb; 20(2):1436-1458. PubMed ID: 37908054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.